skip to Main Content

April 22, 2013

Codexis to Present at 2013 BIO International Convention

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Apr. 22, 2013–
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, announced today that
Gjalt Huisman, Ph.D., Vice President, Pharmaceutical R&D at Codexis,
will present at the 2013 BIO International Convention in Chicago, IL, on
Tuesday, April 23, 2013. Dr. Huisman will present an overview of the
company’s application of its CodeEvolver® directed evolution
technology platform in the field of enzyme therapeutics.

“Codexis’ technology has revolutionized the manufacture of
pharmaceuticals and is currently used in the production of some of the
world’s bestselling drugs. We are now applying our advanced technology
to generate new and improved biologic therapeutics,” said Dr. Huisman.
“Now that we have established the core value that our technology brings,
we are excited to apply our technology platform as the operating system
to generate new and improved therapeutic enzymes in a broad array of
applications. We may evaluate opportunities in a number of therapeutics
areas, such as enzyme replacement, metabolic pool depletion, celiac
disease and antibody therapies.”

Event: 2013 BIO International Convention’sBIO Business Forum
Tuesday, April 23, 2013
Time: 8:15 a.m. Central Time
Chicago Bulls Room; McCormick Place Convention Center; Chicago, IL

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable process development – from
research to manufacturing. For more information, see

Forward-Looking Statements

This press release contains forward-looking statements relating to
Codexis’ ability to deploy its technology platform to generate new and
improved therapeutic enzymes. You should not place undue reliance on
these forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases, beyond
Codexis’ control and that could materially affect actual results.
Factors that could materially affect actual results include Codexis’
need for substantial additional capital in the future in order to expand
its business; Codexis’ dependence on its collaborators; potential
adverse effects to Codexis’ business if its customers’ pharmaceutical
products are not received well in the markets; Codexis’ ability to
develop and commercialize new products for the pharmaceutical markets;
and Codexis’ ability to deploy its technology platform in new adjacent
market spaces. Additional factors that could materially affect actual
results can be found in Codexis’ Annual Report on Form 10-K for the
period ended December 31, 2012 filed with the Securities and Exchange
on April 2, 2013, including under the caption “Risk Factors.”
Codexis expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.

Source: Codexis, Inc.

For Codexis, Inc.
Jemma Connor, +44 161 359 3255
Cox, 212-362-1200

Back To Top
Close search